drugset / Trial / NCT00298012
Methotrexate in the Treatment of Axial Spondyloarthritis
Phase 4
Withdrawn
120 enrolled
Rheumatism Foundation Hospital
Orion Corporation, Orion Pharma · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The goal of this study is to evaluate the efficacy of oral methotrexate for the treatment of active axial spondyloarthritis (early ankylosing spondylitis or spondyloarthritis with sacroiliitis). Efficacy will be measured by reduction in the signs and symptoms of active spondyloarthritis including effects on back pain and stiffness, range of motion in the spine, physical function, quality of life and incidence of arthritis, enthesitis and anterior uveitis.
Timeline
- Start
- 2006-03
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | 15 mg | Oral |
| Subject | Methotrexate | Small molecule | 20 mg | Oral |